Chocolate manufacturer Barry Callebaut secured the positive opinion from EFSA.
Barry Callebaut (Zurich, Switzerland) just secured a positive opinion for a health claim for cocoa flavanols and healthy blood flow. The health claim will be the first earned for cocoa in the European Union.
Raw cocoa beans are highly concentrated with flavanols. When derived from cocoa, these plant compounds have been linked to potential benefits for cognition and mood, cholesterol, blood pressure, and blood circulation.
EFSA (Parma, Italy) concluded that enough data is available to support a link between cocoa flavanol consumption and the maintenance of normal endothelium-dependent vasodilation. In fact, several studies suggest that consuming high amounts of cocoa flavanols can support healthy blood flow even in at-risk populations, such as smokers, overweight subjects, diabetics, and the elderly.
Efficacy, however, appears to rely on very high amounts of cocoa flavanols.
Because traditional chocolate manufacturing relies on high-heat processing which can destroy flavanols, companies like Barry Callebaut have focused their efforts on creating advanced processes that retain high amounts of flavanols in finished cocoa and chocolate ingredients. EFSA’s opinion is based on findings with Barry Callebaut’s ACTICOA process, which the company says preserves up to 80% of raw cocoa flavanols.
In order to obtain the claimed effect on healthy blood circulation, EFSA recommends daily consumption of 200 mg of cocoa flavanols (2.5 g of high-flavanol cocoa powder or 10 g of high-flavanol dark chocolate).
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.